The assessment of tocilizumab therapy on recurrent attacks of patients with familial Mediterranean fever: A retrospective study of 15 patients.

Seda Yurumez Emre Tekgöz Muhammet Çınar Sedat Yilmaz

Published in: Modern rheumatology (2020)

Tocilizumab is found to be efficient on improvement of amyloidosis and decreasing the frequency of recurrent attacks in patients with FMF. Besides, TCZ is well tolerated among the patients. Further and prospective studies with larger sample are needed to support these results.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
rheumatoid arthritis
prognostic factors
stem cells
bone marrow
smoking cessation
disease activity